Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?  

作　　者：Faiza Ahmed Faiza Zakaria Godsgift Enebong Nya Mohamad Mouchli 

机构地区：[1]Division of Clinical and Translational Research,Larkin Community Hospital-Larkin Healthcare Systems,South Miami,FL 33143,United States [2]Department of Internal Medicine,Dow Medical College,Karachi 75400,Pakistan [3]Department of Gastroenterology,John Hopkins Hospital,Baltimore,MD 21218,United States [4]Department of Gastroenterology,Cleveland Clinic,Cleveland,OH 44195,United States

出　　处：《World Journal of Gastrointestinal Surgery》2022年第8期862-866,共5页世界胃肠外科杂志（英文版）（电子版）

摘　　要：Liver transplantation(LT) withstands as the most preferred therapeutic option for patients afflicted with hepatocellular carcinoma(HCC) and cirrhosis. To improve prognosis post-transplant, as well as to prevent the occurrence of rejection, a lifelong immunosuppression strategy is implemented. The following letter to the editor highlights and provides novel evidence from recently published literature on topics discussed within the review article titled “Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma” in World J Gastrointest Surg 2021;13: 953-966. In the recent manuscript, the authors compared immunosuppressive drugs such as the newer option first-generation mammalian target of rapamycin inhibitor, also known as sirolimus, with the most widely used first-generation calcineurin inhibitors, such as tacrolimus(TAC). TAC is commonly known as the most effective immunosuppressive drug after LT, but it has been reported to cause intolerable side effects such as nephrotoxicity,neurotoxicity, diabetes, hypertension, gastrointestinal disturbances, increased risk of infections, and malignancies. It is necessary for physicians to be aware of recent advances in tacrolimus and sirolimus therapies to compare and understand distinctly the effectiveness and tolerability of these drugs. This will assist clinicians in making the best treatment decisions and improve the clinical prognosis of LT recipients with HCC.

关 键 词：RAPAMYCIN TACROLIMUS SIROLIMUS IMMUNOSUPPRESSANTS Hepatocellular carcinoma Liver transplantation 

分 类 号：R735.7[医药卫生—肿瘤]